High-Dose Chemotherapy for Breast Cancer

Annals of Internal Medicine

Volumn 125, Issue 7, 1996, Pages 599-604

  Gradishar, William J ^a,b   Tallman, Martin S ^b   Abrams, Jeffrey S ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BONE MARROW TRANSPLANTATION; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS;

EID: 0030268389     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-7-199610010-00010     Document Type: Review

References (55)

1. Rowlings PA, Antman KS, Horowitz SF, Williams KK, Fields KA, Sobocinski JO, et al. Prognostic factors in autotransplants for breast cancer [Abstract]. Proceedings of the American Society of Clinical Oncology. 1996; 14:325.
2. Jones VE, Raghaven D. Quantum leaps in treatment of high-risk breast cancer? Prove it! Eur J Cancer. 1993;29A:1488-93.
3. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hemalopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483-9.
4. Kennedy MJ. High-dose chemotherapy of breast cancer: is the question answered? [Editorial] J Clin Oncol 1995;13:2477-9.
5. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol. 1992; 10:657-70.
6. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M, et al. A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy [Abstract]. Breast Cancer Res Treat. 1996;37(Suppl 35):11.
7. Canellos GP. Autologous bone marrow or stem-cell transplantation following high-dose chemotherapy for breast cancer: what is the true story? Breast Disease: A Year Book Quarterly. 1995;6:19-20.
8. Rajagopal S, Goodman PJ, Tannock IF. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. J Clin Oncol. 1994;12:1296-304.
9. Patient Referral to the National Cancer Institute's Autologous Bone Marrow Transplantation Clinical Trials: The Physician's Perspective. A Report on Focus Groups and In-Depth Interviews Conducted at the American Society of Clinical Oncology National Meeting, May 1995. Bethesda, MD: Office of Cancer Communications, National Cancer Institute; 1995.
10. Mathews J. NCI survey explores the M.D.'s perspective on ABMT trials [News]. J Natl Cancer Inst. 1995;87:1510-1.
11. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-76.
12. Jones RB, Shpall EJ, Ross M, Bast R, Affronti M, Peters WP. AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support for advanced breast cancer. Current results [Abstract]. Proceedings of the American Society of Clinical Oncology. 1990;9:9.
13. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102-10.
14. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol. 1989;7:1824-30.
15. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920-6.
16. Mulder NH, Mulder PO, Sleijfer DT, Willemse PH, van der Ploeg E, Dolmsa WV, et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer. 1993;29A:668-71.
17. Dunphy FR, Spitzer G. Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst. 1992;84:128-9.
18. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994;12:37-44.
19. Rahman Z, Frye D, Buzdar A, Hortobagyi G. Retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy on the outcome of patients with metastatic breast cancer [Abstract]. Proceedings of the American Society of Clinical Oncology. 1995;14:95.
20. Hortobagyi GN. High-dose chemotherapy is not an established treatment for breast cancer. Chicago: American Society of Clinical Oncology; 1995: 341-6
21. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45:2917-24.
22. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-7.
23. Fisher B, Bauer M, Margolese R, Poisson R, Pitch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665-73.
24. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
25. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978;41:1170-8.
26. Davidson NE, Abeloff MD. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. J Natl Cancer Inst. 1992;84:301-5.
27. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol. 1987;10:387-95.
28. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1995;333:1444-55.
29. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456-61.
30. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:71-85.
31. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. J Clin Oncol 1993;11:580-5.
32. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994;73:2157-67.
33. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995;13:2043-9.
34. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr. 1986;1: 87-94.
35. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10-5.
36. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988;6:1501-15.
37. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-70.
38. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-9.
39. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized clinical trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988; 6:1377-87.
40. Hudis C, Seidman A, Raptis G, Currie V, Baselga N, Sklarin N, et al. Sequential doxorubicin, paditaxel, and cyclophosphamide in women with resected breast cancer and ≥4 positive lymph nodes [Abstract]. Proceedings of the American Society of Clinical Oncology. 1995;14:113.
41. Basser RL, Bik To L, Begley G, Juttner CA, Maher DW, Szer J, et al. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and Filgastrim-mobilized peripheral blood progenitor cells. Clinical Cancer Research. 1995;1:715-22.
42. de Graaf H, Willemse PH, de Vries EG, Sleijfer DT, Mulder PO, van der Graaf WT, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1994;30A:150-3.
43. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132-43.
44. Peters WP, Berry D, Vredenburgh JJ, Hussein A, Rubin P, Elkordy M. Five-year follow-up of high-dose combination alkylating agents with autologous bone marrow transplantation as consolidation after standard-dose cyclophosphamide, doxorubicin and fluorouracil for primary breast cancer involving ≥10 axillary lymph nodes (Duke/CALGB 8782) [Abstract]. Proceedings of the American Society of Clinical Oncology. 1995;14:317.
45. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;14:66-9.
46. Ung O, Langlands AO, Barraclough B, Boyages J. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol. 1995;13:435-43.
47. Bezwoda WR, Dansey R, Seymour L. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology. 1989;46:208-11.
48. Spiridonidis CH, Laufman LR, Rhodes V, Jones J. High-dose chemotherapy for breast cancer [Letter]. J Clin Oncol. 1996;14:686.
49. Cohen MH. Dose-intensive metastatic breast cancer chemotherapy [Letter]. J Clin Oncol. 1996;14:685-86.
50. Benson AB 3d, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center Study. J Clin Oncol. 1991;9:2067-75.
51. Hellman S, Hellman DS. Of mice but not men. Problems of the randomized clinical trial. N Engl J Med. 1991;324:1585-9.
52. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-6.
53. Passamani E. Clinical trials - are they ethical? N Engl J Med. 1991;324:1589-92.
54. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-5.
55. Belanger D, Moore M, Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol. 1991;9: 7-16.